title: Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?
abstract: In 1998, the U.S. Food and Drug Administration granted regulatory approval to the first tumor necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active Crohn's disease. As of 2013, there were 3 additional tumor necrosis factor-α antagonists commercially available for the treatment of inflammatory bowel disease in the United States: adalimumab, certolizumab pegol, and golimumab. Despite a vast literature describing both clinical trial and clinical practice experience with these agents, there remain important questions regarding the efficacy and safety of tumor necrosis factor-α antagonists for the treatment of inflammatory bowel disease. These questions and the best available evidence to answer them were discussed during a Cochrane Collaboration session held at the 2013 Digestive Diseases Week annual meeting. This article reviews the data from that session.
authors.affiliation: *Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom; †Robarts Clinical Trials, Inc., San Diego, California; ‡Division of Gastroenterology, University of California San Diego, La Jolla, California; §Center for Inflammatory Bowel Diseases, Virginia Commonwealth University Health System, Richmond, Virginia; ‖Division of Gastroenterology, Department of Medicine, The University of Western Ontario, London, ON, Canada; ¶Robarts Clinical Trials Inc., Robarts Research Institute, The University of Western Ontario, London, ON, Canada and **Departments of Medicine and Epidemiology and Biostatistics, The University of Western Ontario, London, ON, Canada.
authors.forename: Anthony A
authors.initials: AA
authors.lastname: Akobeng
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Bickston
authors.forename: Nilesh
authors.initials: N
authors.lastname: Chande
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Shackelton
authors.forename: Sigrid
authors.initials: S
authors.lastname: Nelson
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha